Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
Aarhus Univ, Dept Biomed, Ole Worms Alle 3, DK-8000 Aarhus, Denmark..
Aarhus Univ, Dept Biomed, Ole Worms Alle 3, DK-8000 Aarhus, Denmark..
Aarhus Univ, Dept Mol Biol & Genet, Gustav Wieds Vej 10, DK-8000 Aarhus, Denmark..
Aarhus Univ, Dept Biomed, Ole Worms Alle 3, DK-8000 Aarhus, Denmark..
Show others and affiliations
2017 (English)In: Nature Communications, ISSN 2041-1723, E-ISSN 2041-1723, Vol. 8, article id 503Article in journal (Refereed) Published
Abstract [en]

Coronary artery disease is the main cause of death worldwide and accelerated by increased plasma levels of cholesterol-rich low-density lipoprotein particles (LDL). Circulating PCSK9 contributes to coronary artery disease by inducing lysosomal degradation of the LDL receptor (LDLR) in the liver and thereby reducing LDL clearance. Here, we show that liver heparan sulfate proteoglycans are PCSK9 receptors and essential for PCSK9-induced LDLR degradation. The heparan sulfate-binding site is located in the PCSK9 prodomain and formed by surface-exposed basic residues interacting with trisulfated heparan sulfate disaccharide repeats. Accordingly, heparan sulfate mimetics and monoclonal antibodies directed against the heparan sulfate-binding site are potent PCSK9 inhibitors. We propose that heparan sulfate proteoglycans lining the hepatocyte surface capture PCSK9 and facilitates subsequent PCSK9: LDLR complex formation. Our findings provide new insights into LDL biology and show that targeting PCSK9 using heparan sulfate mimetics is a potential therapeutic strategy in coronary artery disease.

Place, publisher, year, edition, pages
2017. Vol. 8, article id 503
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:uu:diva-335195DOI: 10.1038/s41467-017-00568-7ISI: 000410237600005PubMedID: 28894089OAI: oai:DiVA.org:uu-335195DiVA, id: diva2:1163659
Available from: 2017-12-07 Created: 2017-12-07 Last updated: 2017-12-07Bibliographically approved

Open Access in DiVA

fulltext(2878 kB)19 downloads
File information
File name FULLTEXT01.pdfFile size 2878 kBChecksum SHA-512
4b3b38eff2009afa8ae41d326d7d73ca88eda56ea51bd27938a2af0a585e0b461119fdbb83d8e0c274ded172b2320d19cbcfa0b6881f2bbab490932ca94d58a1
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Li, Jin-Ping
By organisation
Department of Medical Biochemistry and Microbiology
In the same journal
Nature Communications
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)

Search outside of DiVA

GoogleGoogle Scholar
Total: 19 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 52 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf